Coherus BioSciences, Inc. (CHRS)

2,2200 -0,0500 (-2,20%) Al cierre: 04:00PM EDT

Coherus BioSciences, Inc.

333 Twin Dolphin Drive
Suite 600
Redwood City, CA 94065
United States
650 649 3530
https://www.coherus.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 306

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Dennis M. Lanfear	Chairman, President & CEO	1,82M	179,98k	1955
Mr. Bryan J. McMichael	Interim CFO, Principal Financial and Accounting Officer, SVP-Accounting & Corporate Controller	615,07k	N/A	1979
Mr. Paul Reider	Chief Commercial Officer	854,06k	N/A	1970
Mr. Richard L. Hameister	Chief Technical Officer	N/A	N/A	N/A
Ms. Jami Taylor	Vice President of Investor Relations	N/A	N/A	N/A
Ms. Andy Rittenberg	Executive Vice President of General Counsel	N/A	N/A	N/A
Cheston Turbyfill	Vice President of Communications	N/A	N/A	N/A
Mr. Scott Saywell	Executive Vice President of Corporate Development	N/A	N/A	N/A
Ms. Rebecca Sunshine	Chief Human Resources Officer	N/A	N/A	1963
Mr. Michael Chen	Senior Vice President of Commercial Analytics & Trade	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Gobierno corporativo

El ISS Governance QualityScore de Coherus BioSciences, Inc., a día 1 de mayo de 2024, es 7. Las puntuaciones base son Auditoría: 7; Tablero: 6; Derechos de los accionistas: 8; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.